Drug intelligence / Profile preview

xylooligosaccharide

Development stage
Unknown
Lead developer
Suntory Holdings
Modality
Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
Administration
Oral
01

Overview

Xylooligosaccharide (XOS) is a prebiotic functional oligosaccharide composed of 2–7 xylose units linked by β-1,4 glycosidic bonds. It is produced from the xylan fraction of plant fiber and is not digestible by human enzymes. Instead, it selectively stimulates the growth of beneficial gut bacteria such as bifidobacteria and lactobacilli in the colon[1][3][5]. XOS has been shown in clinical studies to improve digestive health, regulate blood glucose and lipid levels, enhance immune function, promote mineral absorption (such as calcium), and support overall intestinal microecology[1][3][4][6]. It may also have potential roles in preventing or managing cardiovascular disease, diabetes, hyperlipidemia, hypertension, chronic hepatitis, irritable bowel syndrome (IBS), constipation/diarrhea management, osteoporosis, pruritus and certain cancers[4][6]. Commercially available since the 1980s (originally developed by Suntory in Japan), XOS is now widely used as a dietary supplement ingredient due to its stability under food processing conditions and efficacy at low doses (typically 1–4 g/day)[1][8].

Brand names
PreticX
Other names
xylo-oligosaccharideXOSxylo oligosaccharide

Beyond the preview

Go deeper on xylooligosaccharide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on xylooligosaccharide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call